A Phase Ib/II Study of GDC-0068 Or GDC-0980 With Abiraterone Acetate Versus Abiraterone Acetate in Patients With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

Inclusion Criteria:

- Histologically confirmed metastatic or advanced prostate adenocarcinoma that has been
previously treated with docetaxel and has progressed during treatment of at least one
hormonal therapy

- Two rising PSA levels >/= 2 ng/mL measured >/= 1 week apart or radiographic evidence
of disease progression in soft tissue or bone

- ECOG performance status of 0, 1, or 2

- Adequate hematologic and organ function

- Documented willingness to use an effective means of contraception

Exclusion Criteria:

- History of Type I or Type II diabetes mellitus requiring insulin

- NYHA Class III or IV heart failure or LVEF < 50% or ventricular arrhythmia requiring
medication

- Significant atherosclerotic disease, as evidenced by: unstable angina, history of
myocardial infarction within 6 months prior to Day 1, or cerebrovascular accident
within 6 months prior to Day 1 - Active autoimmune disease that is not controlled by
nonsteroidal anti inflammatory drugs or active inflammatory disease which requires
immunosuppressive therapy

- Clinically significant history of liver disease

- History of adrenal insufficiency or hyperaldosteronism

- Phase II only: Previous therapy for prostate cancer with CYP17 inhibitors, including
abiraterone

- Phase II only: Previous treatment for prostate cancer with Akt, PI3K, and/or mTOR
inhibitors

- Need for chronic corticosteroid therapy of >/= 20 mg of prednisone per day or an
equivalent dose of other anti inflammatory corticosteroids or immunosuppressant